Baker Tilly works closely with stakeholders across the healthcare industry spectrum, including health plans, providers and life sciences companies, and can help mitigate a variety of issues that may arise from the spread of COVID-19.
The impact of the pandemic is stressing healthcare provider supply chains for items in high demand such as face masks and anti-bacterial sprays. Baker Tilly can help identify alternative suppliers for key medical goods when shortages occur or work with those organizations who are impacted by the President invoking the Defense Production Act.
And, while there is no vaccine for the coronavirus yet, Baker Tilly is well-situated to negotiate rapid testing, and drug or vaccine reimbursement with payers if the need arises.
Baker Tilly can also help your institution conduct or complete your clinical trial if you are seeing a decline in patient numbers through one of our creative patient engagement solutions.
In addition, the manner in which commercial and medical affairs professionals engage physicians and hospital systems is already evolving and will go through a rapid transformation that will persist beyond the COVID-19 pandemic. Baker Tilly can help your organization achieve this transformation by assisting with:
Life sciences companies are on the forefront of the public health response to COVID-19.
With business leadership focused on critical operational needs, Baker Tilly is helping our life sciences clients maintain an open dialogue with state and local government agencies regarding business, operational and financial needs.